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Abstract 
The introduction and adoption of new technology in medicine is a continuous ever present process but it is often not 
studied. Insights gained from documenting such experiences can not only guide local practices but also provide valuable 
quality benchmarks. Automated control of FiO2 based on continuous SpO2 (A-FiO2) not only reduces the challenging task 
of manual oxygen titration, but also has the potential to greatly improve the morbidity and mortality of extremely preterm 
infants. First approved for use in Europe in 2012, it is now available on most infant ventilators outside the USA. Poland 
was the first region in Europe to implement its clinical use. We report experience from 619 infants from 12 centers 
recorded in a web-based registry established in 2013 to document its use. We found the A-FiO2 was primarily used in the 
first week of life in intubated infants. However it is also successfully applied in both noninvasively supported infants and 
in those who were difficult to wean from oxygen and who exhibited frequent desaturations. We also found the SpO2 target 
range and alarm setting are not different from normal manual titration, although wider settings are also used and promise 
some benefit. Finally we report our plan to gather data from a national data base and detailed surveys. The surveys will 
document subjective aspects of this experience from a core group of centers. Details of the surveys are included and 
cover: experience with training and acceptance, changes in practice associated with the years of experience and barriers 
to broader use. 
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Background 
In a broad sense assimilation of technology includes 
many aspects. Adoption characterization includes pur-
chase rate, increasing use rate, as well as initial and 
subsequent refinements of use. The uptake rate of new 
technologies can vary dramatically from less than 
a year to decades. Adoption of new medical technolo-
gies is generally slower than consumer products, often 
a decade or longer, but occasionally very quick. The 
actual adoption of new medical technologies into neo-
natal care has not often been studied. 
A Vermont-Oxford collaborative report showed the 
general changes of use of various modalities in very 
low birth weight infants across a decade [1]. It reported, 
for instance, a steady increase in the use of high fre-
quency ventilation in the 90’s from one of every four-
teen infants to one in four. Two neonatal technologies 
have been carefully studied. The clinical adoption of 
the use of exogenous surfactant was much anticipated 
and quickly put into widespread clinical use and its 
clinical impact documented [2]. Once the effectiveness 
of antenatal steroids was proven there was significant 
pressure to monitor its implementation in high risk 
obstetrics, still the transition took much longer [1]. In 
addition, we previously reported on the rapid adoption 
of a new approach to respiratory support in Poland. 
This included both the clinical impact [3] as well as use 
patterns [4] associated with the assimilation of modern 
non-invasive continuous positive airway pressure 
(CPAP) devices in Poland. Further factors beyond evi-
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dence-based proof of effectiveness that preferentially 
favor the use of different respiratory support modali-
ties, have also been described by one of our research 
team [5]. 
Automated closed loop control of inspired oxygen 
based on SpO2 monitoring (A-FiO2) is a relatively new 
technology and is currently offered by nearly all infant 
ventilator manufacturers. The first units were approved 
for distribution in Europe in 2012, but are not yet 
available in the United States. Because of the timing of 
a widespread program to replace older mechanical 
ventilators in Poland’s NICUs, our adoption was on 
the forefront of introducing A-FiO2 globally. These 
activities involved both research and clinical use. Two 
centers participated in an international trial to evaluate 
A-FiO2 effectiveness [6]. In addition 4 other papers 
from Polish centers have been published [7–10]. One 
described the initial use of A-FiO2 at 5 centers, and 
others were clinical testing. In addition to providing 
funding for many of these A-FiO2 systems, the Great 
Orchestra of Christmas Charity also funded a web-
based registry, similar to that used during the intro-
duction of nCPAP, to monitor the details of the actual 
clinical use of A-FiO2 in a selected group of centers [7]. 
Methods  
In 2013 twenty-one centers agreed to provide de-
tailed data on their use of A-FiO2. This web database is 
described elsewhere [7]. It includes a data set for each 
infant treated. In summary, the data set includes infant 
demographics, baseline clinical status, respiratory sup-
port prior to use of A-FiO2, indication for A-FiO2 use, 
settings and duration of A-FiO2, and subjective impres-
sion of A-FiO2 functions as well as neonatal outcome. 
The aim of this project was to analyze this database 
to provide a representative sample of the use of A-FiO2 
in Poland and how its use might have evolved with 
adoption and extended experience across units. 
Results  
The analysis included 619 case report records. A-
FiO2 systems were used primary in preterm infants 
(83%). It was applied primarily as part of routine care 
(71%). Its indication for non routine uses were weaning 
oxygen (17%) and managing infants with frequent 
desaturations (11%). A-FiO2 was used primarily in 
intubated infants (83%), thought nearly half were 
managed noninvasively at some point prior to starting 
A-FiO2. 
A-FiO2 was primarily used to manage infants with 
gestational ages between 25–31 weeks. However 
overal use reflected a wide range of 22–41 weeks.  
 
Initiation of A-FiO2 was usually in the first 2 days of 
life with an inital inspired oxygen of 30–50%. These 
were not rescue interventions as the maximum oxygen 
requirement in the period before intervention was 
typically higher (40–100%). 
The most common control range was 90–95% SpO2, 
which was rarely changed during management (5%). 
Although ranges were at times set much wider. The 
high SpO2 alarm was most commonly set between 95–
98% SpO2. The low alarm was typically set between 
85–88%. Although they were at times set much wider. 
A-FiO2 was typically used between 1 and 7 days, but 
as long as 59 days. 
A-FiO2 was rated as effective in nearly all cases 
(25% very effective, 72% effective). It was only 
reported as ineffective in 3 of the 619 cases. In most 
cases the alarms were rated as being frequent but not 
persistent (71%) and infrequent or rare 21% of the time. 
In 8% of the cases the alarms were rated as excessive 
(frequent and persistent). This was much more com-
mon (22%) when the alarms were set close to the SpO2 
control range. 
We were aware that only 12 of the 21 centers that had 
agreed to participate in the registry had documented 
use. With this review we found that only 5 has 
registered cases throughout the intended period (2014–
2019). These 5 sites had, in fact, contributed all but 3% 
of the cases, and nearly all of these were between 2014 
and 2017. While 619 is still a robust experience, we 
decided that evaluation of trends in use across years or 
within centers were inappropriate without further 
assessment of compliance with prospective enrollment 
in each center across the years. 
Discussion  
We reported on the aggregate experience of the use 
of A-FiO2 with 619 infants, mostly from 5 centers 
between 2014 and 2017. Its application is primarily for 
routine management of intubated infants in the first 
days of life, though it is used also with success in 
infants who are not intubated and also who have 
difficulty weaning oxygen or have frequent desatu-
rations. These findings are consistant with the report of 
our initial experience [7]. 
This analysis has limitations. First it is unclear 
whether our report, while reflecting a large number of 
infants, is a sample of convenience or truly reflective 
of A-FiO2 use. That is, was the experience different in 
centers with system but not reporting, or with subjects 
not reported by participating centers? For that reason 
and also because it reflects the experience of 5 centers, 
it is not clear whether it can be projected to the several 
hundred centers that routinely intubate and ventilate 
babies in Poland. 
In consideration of those limitations, in the summer 
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 of 2019 we decided to extend and broaden this project 
to provide a truly representive picture of the adoption 
of A-FiO2 in Poland. To accomplish this we deemed it 
necessary to collect and integrate disparate information 
describing the level of adoption of A-FiO2 as well as 
how it is used and perceived. 
We believe this should be of broad academic interest 
for two reasons. First, the impact of SpO2 targeting 
on neonatal outcomes has been widely studied [11]. 
However, the published evaluations of A-FiO2 have 
been less comprehensive. These A-FiO2 studies have 
focused on the control of SpO2 over a short period of 
time (i.e., 2.5–24 hours) and mostly in carefully 
controlled settings [12]. Though these studies have 
consistently reported excellent effectiveness, there 
have only been a few reports of its routine use 
[7, 9, 13]. While of great potential benefit, the assess-
ment of the impact of A-FiO2 on outcomes is just now 
started [14, 15]. Secondly, the use of A-FiO2 tech-
nology outside of Poland is only beginning, and to our 
knowledge, no center or region has the years of 
experience with routine use that is available from 
Poland. 
There are three sources of data that will be used for 
this extended project. These are national statistics, 
a previously implemented web based database and 
a series of site surveys developed for this project. The 
description of and intended use of each is described in 
the first three sub-sections below. 
Data from Nat ion al  Databases  
Most readers will lack familiarity with neonatal 
healthcare environment in Poland, therefore a short 
description needs to be provided. This overview will 
include the number of special care nurseries, number of 
admissions and some details on the hierarchy of the 
levels of care. The latter categorization will make use 
of ICD-9 codes. These data are available from the 
National Health Fund, and the Neonatal Society. We 
also defined advanced respiratory support as routinely 
intubating infants and providing extended respiratory 
support. This would exclude centers from this higher 
category when they only intubate as part of a transport 
effort, or for surfactant administration. 
Data from Web-b ased r egistr y  
Subjective information (Table 1) will be used to 
evaluate compliance, which is the degree of complete 
participation. We did observe a ramp up in use of the 
registry at the beginning in 2013 and also a tailing off 
starting in 2018. We will evaluate to what degree this 
reflects use of A-FiO2, or compliance with reporting. 
After excluding centers that were not compliant with 
their obligation or for some reason A-FiO2 access be-
came unavailable, we expect to be left with a robust 
multicenter sample of about 500–600 cases. We have 
defined this group as the Participating Centers. 
Site  sur veys  
Written survey instruments were developed in En-
glish and approved in October. They have been trans-
lated to Polish and will be sent to appropriate centers in 
early 2020. When completed they will be reviewed by 
the project team, with clarification sought as needed. 
After these are culled, it is expected there will be 
between 200–250 confirmed in the Advanced Respi-
ratory category and that about 10% will have A-FiO2 
experience. This data on these Advanced Respiratory 
support centers will include the size of the unit and 
annual admissions as well as the number of invasive 
and noninvasive respiratory devices. 
In addition, for the centers with A-FiO2 experience, 
a survey will include information about the number and 
type of A-FiO2 systems and their year of acquisition. 
For those centers with A-FiO2 experience, a summary 
of their current opinion about its use will be gathered, 
using a ranked Likert scale. As shown in Table 2ab, this 
includes 10 questions covering its perceived effective-
ness, training and indications for use. 
Additional information about their experience and 
opinions will be gathered from these Participating 
Centers. These questions are shown in Tables 3a–g. 
Table 3a addresses 5 areas of perceived benefits, and 
limitations of performance and support. Table 3b–c 
explore ideal indications for use and barriers to their 
adoption. Table 3d evaluates potential problems with 
use. Table 3e explores changes in use based on experi-
ence. Table 3f documents its initial implementation and 
Table 3g current practices. 
This survey will be sent to the Participating Centers 
as they are identified. Care will be taken to insure that 
the responses represent the opinions in the unit, and not 
just of the chief, or a research coordinator. The survey 
instrument provides an opportunity for reporting diver-
gent opinions. We expect there might be different 
opinions among nurses and among physicians, and also 
between the two groups. To further encourage this, 
a request will be made for each site to meet and discuss 
the scaling of each answer and further to record diver-
gent opinions. The implementation of this process will 
be monitored, and a team member will visit each site, 
either to audit compliance or to participate in the 
gathering and reconciliation of opinions. 
Stat ist ica l  an alys is   
Summary descriptive data will be provided for each 
of the groups of centers. Analyses will focus on the 
Participating Centers (estimated 500–600 cases from 
5 centers). These analyses will address potential differ-
ences among centers, differences associated with 
indications for use, and changes in practice over time. 
A value of p<0.05 will be considered statistically sig-
nificant. The data will be compiled in an excel data-
base. Tabulation and analyses will be performed with 
XLSTAT (v20, Addinsoft Paris France). 
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Table 1: Assessment of Compliance. 
Does enrollment reflect actual use? 
2014 Complete (>90%)  ☐☐☐☐☐  No <10%) 
2015 Complete (>90%)  ☐☐☐☐☐  No <10%) 
2016 Complete (>90%)  ☐☐☐☐☐  No <10%) 
2017 Complete (>90%)  ☐☐☐☐☐  No <10%) 
2018 Complete (>90%)  ☐☐☐☐☐  No <10%) 
2019 Complete (>90%)  ☐☐☐☐☐  No <10%) 
For each year, if NO, why not? ___________  
if Complete, why not more? __________ 
Table 2: Overview: Assessment of A-FiO2 experience. 
a) Rate current subjective impressions about A-FiO2 use 
How often is A-FiO2 used: Routinely ☐☐☐☐☐  Never 
Effectiveness of A-FiO2: Excellent  ☐☐☐☐☐  Poor 
Effectiveness of Alarms: Excellent  ☐☐☐☐☐  Excessive 
A-FiO2 ever erratic: Never       ☐☐☐☐☐  Regularly 
Rate of acceptance by staff: Quickly     ☐☐☐☐☐  Resistant 
Training by distributor: Excellent  ☐☐☐☐☐  Insufficient 
b) Current Indications for use 
all infants receiving respiratory support: Yes ☐☐☐☐☐  No 
all unstable infants receiving respiratory support: Yes ☐☐☐☐☐  No 
only intubated infants: Yes ☐☐☐☐☐  No 
only preterm infants: Yes ☐☐☐☐☐  No 
Table 3: Detailed experience from Participating Center. 
a) About the benefits of A-FiO2? 
better maintenance of SpO2 in normoxemia Yes ☐☐☐☐☐  No 
reducing episodes of extreme SpO2 exposure Yes ☐☐☐☐☐  No 
reducing the risk of periodic nurse distraction Yes ☐☐☐☐☐  No 
reducing nursing work load Yes ☐☐☐☐☐  No 
reducing false/nuisance SpO2 alarms Yes ☐☐☐☐☐  No 
b) About infants whom A-FiO2 should ideally be used? 
all infants receiving respiratory support: Yes ☐☐☐☐☐  No 
all unstable infants receiving respiratory support: Yes ☐☐☐☐☐  No 
only intubated infants: Yes ☐☐☐☐☐  No 
only preterm infants: Yes ☐☐☐☐☐  No 
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c) About why A-FiO2 is not used more in this unit? 
not enough systems with A-FiO2: Yes ☐☐☐☐☐  No 
A-FiO2 limited to intubated and NIPPV: Yes ☐☐☐☐☐  No 
some clinicians do not prefer the vent with A-FiO2: Yes ☐☐☐☐☐  No 
some clinicians do not like A-FiO2: Yes ☐☐☐☐☐  No 
clinicians do not like the higher alarm frequency: Yes ☐☐☐☐☐  No 
A-FiO2 is not always effective: Yes ☐☐☐☐☐  No 
lack of adequate training on use of A-FiO2: Yes ☐☐☐☐☐  No 
d) About problems with A-FiO2 
excessive alarm frequency (alarm fatigue) Yes ☐☐☐☐☐  No 
over reliance on automatic control (ignoring alarms) Yes ☐☐☐☐☐  No 
A-FiO2 increase of FiO2 masked clinical deterioration Yes ☐☐☐☐☐  No 
erratic SpO2 control Yes ☐☐☐☐☐  No 
A-FiO2 function stopped Yes ☐☐☐☐☐  No 
A-FiO2 SpO2 reading different from SpO2 monitor Yes ☐☐☐☐☐  No 
Any other problem Yes ☐☐☐☐☐  No 
For any of these not NO, discuss and describe both details and frequency 
e) About changes in your use of A-FiO2 that came with increased experience 
Setting level for the control range Yes ☐☐☐☐☐  No 
Setting of the SpO2 alarm thresholds Yes ☐☐☐☐☐  No 
Setting of the SpO2 alarm delay Yes ☐☐☐☐☐  No 
Indications for use (infant size, diagnosis, acuity) Yes ☐☐☐☐☐  No 
For any of these not NO, discuss and describe details including whether it 
was unit wide or related to individual clinicians. 
f) About the initial integration of A-FiO2 into your unit 
Did you receive training from the distributor or manufacture Yes  ☐ No ☐ 
Was the initial training adequate? Yes ☐☐☐☐☐  No 
Time between training and start of routine use _______ weeks 
How long is the orientation for physicians new to A-FiO2 _______ hours 
How long is the orientation for nurses new to A-FiO2 _______ hours 
g) About the current use of A-FiO2 in your unit? 
Prescribed target ranges are part of the medical record Yes  ☐ No ☐ 
Prescribed SpO2 alarm levels are part of the medical record Yes ☐☐☐☐☐  No 
A-FiO2 is turned on or off only by the attending physician Yes ☐☐☐☐☐  No 
Target Ranges are set or reset only by the attending physician Yes ☐☐☐☐☐  No 
Alarm delays are set or reset only by the attending physician Yes ☐☐☐☐☐  No 
SpO2 Alarm delays are usually set at ______  seconds 
SpO2 Alarm delays are on occasion set between _______-_______ s 
 
References 
[1] Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality 
and morbidity for very low birth weight infants, 1991–1999. 
Pediatrics. 2002; 110:143–51. DOI: 10.1542/peds.110.1.143 
[2] Schwartz R, Luby A, Scanlon J, Kellogg R. Effect of surfactant 
on morbidity, mortality, and resource use in newborn infants 
weighing 500 to 1500 grams. N Engl J Med. 1994; 330:1476–
80. DOI: 10.1056/NEJM199405263302102 
[3] Swietlinski J, Bober K, Gajewska E, et al. Introduction of Infant 
Flow nasal continuous airway pressure as the standard of 
practice in Poland: the initial 2-year experience. Pediatr Crit 
Care Med. 2007; 8(2):109–14. 
DOI: 10.1097/01.PCC.0000257096.57260.3F 
[4] Wilinska M, Bachman T, Swietlinski J, et al. Impact of the shift 
to neonatal noninvasive ventilation in Poland: a population 
study. Pediatr Crit Care Med. 2014; 15(2):155–61. 
DOI: 10.1097/PCC.0b013e3182a125f3 
[5] Bachman TE, Marks NE, Rimensberger PC. Factors effecting 
adoption of new neonatal and pediatric respiratory technolo-
 
124 
 
Lekar a technika – Clinician and Technology 2019, vol. 49(4), pp. 119–124, DOI: 10.14311/CTJ.2019.4.03 
ISSN 0301-5491 (Print), ISSN 2336-5552 (Online) 
ORIGINAL RESEARCH 
gies. Intensive Care Med. 2008; 34:174–8. 
DOI: 10.1007/s00134-007-0914-6 
[6] van Kaam AH, Hummler H, Wilinska M, et al. Automated 
versus manual oxygen control with different saturation targets 
and modes of respiratory support in preterm infants. J Pediatr. 
2015; 167(3):545–50. DOI: 10.1016/j.jpeds.2015.06.012 
[7] Wilinska M, Skrzypek M, Bachman T, et al. Using the auto-
mated FiO2-SpO2 control in neonatal intensive care units in 
Poland: a preliminary report. Developmental Period Medicine. 
2015; XIX,3(216):263–70. 
[8] Wilinska M, Bachman T, Swielinski J, et al. Quicker response 
results in better SpO2 control – a comparison of 3 FiO2-titration 
strategies in ventilated preterm infants. Ann Agric Environ 
Med. 2015;22(4):708–12. DOI: 10.5604/12321966.1185781 
[9] Warakomska M, Bachman TE, Wilinska M. Randomized 
evaluation of two SpO2 alarm strategies during automated FiO2 
control in the NICU. BMC Pediatr. 2019; 19:142. 
[10] Wilinska M, Bachman T, Swietlinski J, et al. Automated FiO2-
SpO2 control system in neonates requiring respiratory support: 
a comparison of a standard to a narrow SpO2 control range. 
BMC Pediatr. 2014; 14:130. DOI: 10.1186/1471-2431-14-130 
[11] Askie LM, Darlow BA, Finer N, et al. Association between 
oxygen saturation targeting and death or disability in extremely 
preterm infants in the Neonatal Oxygenation Prospective Meta-
analysis Collaboration. JAMA. 2018; 319(21):2190–201. DOI: 
10.1001/jama.2018.5725 
[12] Mitra S, Singh B, El-Naggar W, McMillan DD. Automated 
versus manual control of inspired oxygen to target oxygen 
saturation in preterm infants: a systematic review and meta-
analysis. J Perinatol. 2018; 38(4):351–60. 
DOI: 10.1038/s41372-017-0037-z 
[13] van Zanten HA, Kuypers KL, Stenson BJ, et al. The effect of 
implementing an automated oxygen control on oxygen satu-
ration in preterm infants. Arch Dis Child Fetal Neonatal Ed. 
2017: 0:F1–5. DOI: 10.1136/archdischild-2016-312172 
[14] Poets CF, Franz AR. Automated FiO2 control: nice to have, or 
an essential addition to neonatal intensive care? Arch Dis Child 
Fetal Neonatal Ed. 2017;102:F5–6. 
DOI: 10.1136/archdischild-2016-311647 
[15] Maiwald CA, Niemarkt HJ, Poets CF et al. Effects of closed-
loop automatic control of the inspiratory fraction of oxygen 
(FiO2-C) on outcome of extremely preterm infants – study 
protocol of a randomized controlled parallel group multicenter 
trial for safety and efficacy. BMC Pediatr. 2019; 19, 363. DOI: 
10.1186/s12887-019-1735-9 
Thomas E. Bachman MSc. 
Department of Biomedical Technology 
Faculty of Biomedical Engineering 
Czech Technical University in Prague 
nám. Sítná 3105, CZ-272 01 Kladno 
& 
Economedtrx 
www.medtrx.org 
Lake Arrowhead, CA USA 92352-1269 
 
E-mail: tbachman@me.com 
thomas.bachman@fbmi.cvut.cz 
Phone: +1 909 337-0828
 
